Register for OBR daily


To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

ONTY $1.90 0.1700 +9.83%
AGIO $72.90 4.6500 +6.81%
NWBO $5.09 0.2500 +5.17%
GALE $1.92 0.0900 +4.92%
MYGN $36.68 1.6800 +4.80%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

CVM $0.69 -0.1619 -19.05%
IMGN $8.84 -0.6200 -6.55%
INO $11.55 -0.6400 -5.25%
APRI $1.56 -0.0800 -4.88%
CERU $4.30 -0.1900 -4.23%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next > | Last >>

Petition Calls on Roche to Cut Breast Cancer Drug Price

(Reuters) Oct 21, 2014 - A British-led petition signed by 29,000 people has demanded that Switzerland's Roche, the world's biggest maker of cancer medicines, cut the price of its expensive new breast cancer drug Kadcyla.
read article 

Herceptin Boosts Survival for Breast Cancer: Study

(WebMD/HealthDay News) Oct 20, 2014 - Adding the drug Herceptin to chemotherapy for certain breast cancer patients increases overall survival and reduces the risk of recurrence compared to chemotherapy alone, new research shows.
read article 

Lilly CEO Sees Light After a Difficult Year

(Wall Street Journal) Oct 19, 2014 - Eli Lilly & Co. is deep into what Chief Executive John C. Lechleiter calls the “toughest year” in the drug maker’s 138-year history. Revenue at Lilly has plunged because of generic competition that followed patent expirations for several of its top-selling drugs, including the antidepressant Cymbalta.
read article (paid subscription required) 

Sanofi, Regeneron Start Phase 3 Trial of Dupilumab in Eczema

(Reuters) Oct 20, 2014 - French drugmaker Sanofi and its U.S. partner Regeneron said on Monday they had started a Phase III clinical study of their experimental drug dupilumab in patients with atopic dermatitis.
read article 

First Detailed Look at Celgene Crohn's Disease Pill Impresses

(TheStreet) Oct 20, 2014 - As a pill, Celgene's GED-031 (also known as mongersen) has the potential to become a preferred Crohn's therapy over injectable drugs like Abbvie's top-selling Humira.
read article 

U.S. To Temporarily Halt Funding For Controversial Virus Research

(NPR/Shots blog) Oct 17, 2014 - The federal government will suspend funding while it reviews the potential risks and benefits of certain experiments with three viruses: SARS, MERS and influenza.
read article 

Susan B. Komen Targets a New Generation

(Wall Street Journal) Oct 19, 2014 - When Susan G. Komen’s president and chief executive, Judith A. Salerno, took over the nonprofit a year ago, the Dallas-based breast-cancer group was just emerging from its worst fundraising and public-relations crisis.
read article (paid subscription required) 

Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive

(PRWeb) Oct 20, 2014 - Renowned cancer center and OncLive will work together to provide oncology professionals with information and resources they can use to advance patient care.
read press release 

NCCN Chemotherapy Order Templates to Be Integrated Into Epic's Electronic Health Record

(NCCN) Oct 20, 2014 - The National Comprehensive Cancer Network® (NCCN®) is working with Epic to integrate the NCCN Chemotherapy Order Templates (NCCN Templates®) into Epic's Beacon Oncology Information System as electronic chemotherapy protocols for use by health care providers.
read press release 

Discussing Lung Cancer Screening at #ACCC2014

(ACCCBuzz) Oct 20, 2014 - A small group Think Tank convened at the 2014 ACCC National Oncology Conference focused on key questions around lung cancer screening and how cancer programs are developing lung cancer screening programs.
read article 

Kaiser Permanente Southern California Pledges to Cut Colorectal Cancer Deaths in Half

( Oct 17, 2014 - Kaiser Permanente Southern California announced today at the American Society of Clinical Oncology Quality Care Symposium in Boston, that it is committed to cutting the number of colorectal cancer deaths in half by 2023.
read article 

Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer

(Yahoo! Finance) Oct 20, 2014 - Taiho Oncology, Inc. announced that the FDA granted Fast Track designation for TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug under investigation for the treatment of refractory metastatic colorectal cancer (mCRC), and that the Company has initiated a rolling NDA submission to the FDA.
read article 

Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA® for Waldenstrom's Macroglobulinemia

(Pharmacyclics) Oct 20, 2014 - Pharmacyclics, Inc. today announced that it has submitted a supplemental New Drug Application (sNDA) to the FDA based on data from a Phase 2 study evaluating the use of IMBRUVICA® (ibrutinib) in patients with Waldenstrom's macroglobulinemia (WM).
read corporate press release 

Phase 2 Data for Progenics' 1404 Imaging Agent Presented at EANM Congress

(CNNMoney) Oct 20, 2014 - Trial data show 1404 more sensitive than MRI in detecting primary and metastatic prostate cancer; phase 1 and 2 data featured in two oral presentations, selected for highlights lecture.
read article 

Liquid Biopsies Gain Ground as an Alternative

(Philadelphia Inquirer) Oct 13, 2014 - Cancer-tissue biopsies are no fun. Ask Christine Walsh, 48, of Bedminster, whose cancer began in her left breast in 2008 and eventually spread to her skin. Injecting lidocaine to numb her chest for a biopsy proved painful, as were the procedure and stitches that followed.
read article 

Many Older People Have Mutations Linked to Leukemia, Lymphoma in Their Blood Cells

(WUSTL) Oct 20, 2014 - At least 2 percent of people over age 40 and 5 percent of people over 70 have mutations linked to leukemia and lymphoma in their blood cells, according to new research at Washington University School of Medicine in St. Louis.
read article 

New Study Demonstrates Advances in Creating Treatment for Common Childhood Blood Cancer

(NYU Langone) Oct 20, 2014 - Researchers at NYU Langone Medical Center conclude new drug in development may offer first alternative to standard chemotherapy for T-Cell Acute Lymphoblastic Leukemia.
read press release 

70-Gene Signature Not Cost-Effective in Breast Cancer

(Betty Hardwick Center/HealthDay News) Oct 17, 2014 — For patients with node-negative breast cancer (NNBC), the 70-gene signature is unlikely to be cost-effective for guiding adjuvant chemotherapy decision making, according to a study published online Oct. 6 in the Journal of Clinical Oncology.
read article 

NewLink in $1 Billion Deal with Roche to Develop Cancer Drug

(Reuters) Oct 20, 2014 - NewLink Genetics Corp said it entered into an agreement with Roche Holding AG to develop NewLink's cancer immunotherapy, making the Ebola vaccine developer eligible to receive over $1 billion in milestone payments.
read article 

DNA Said to Protect Hispanic Women From Breast Cancer

(Wall Street Journal) Oct 20, 2014 - A genetic trait protects many women of Latin American descent from breast cancer, researchers probing the ethnic biology of cancer said Monday.
read article (paid subscription required) 

Genetic Variant Protects Some Latina Women from Breast Cancer

(UCSF News) Oct 20, 2014 - An international research collaboration led by UC San Francisco researchers has identified a genetic variant common in Latina women that protects against breast cancer.
read article 

Urge Your Representative to Support SGR Repeal

(ASCO in Action) Oct 17, 2014 - Representatives Reid Ribble (R-WI) and Kurt Schrader (D-OR) are asking fellow Representatives to sign a letter to leadership of the House of Representatives asking them to take action this year to eliminate the flawed sustainable growth rate (SGR) formula used to set Medicare physician payments and enact fiscally responsible reforms to the system.
read article 

CMS to Reopen Meaningful Use Hardship Exemption; Deadline to Attest Extended to Nov. 30

(ASCO in Action) Oct 17, 2014 - The Centers for Medicare & Medicaid Services (CMS) this week announced the reopening of its Meaningful Use (MU) hardship exception application for physicians and hospitals to avoid the 2015 penalty.
read article 

FDA Panel: Chantix Boxed Warning Should Stay

(MedPage Today) Oct 16, 2014 - An FDA advisory committee voted overwhelmingly that the stop-smoking drug should continue to carry a boxed warning about the risk of severe neuropsychiatric events, with several panel members suggesting it should be strengthened.
read article (free registration required) 

Chimerix Gets FDA OK to Test Drug For Ebola

(ABC News/Associated Press) Oct 17, 2014 - A North Carolina drugmaker plans to test its experimental antiviral drug in patients who have Ebola, after getting authorization from regulators at the Food and Drug Administration.
read article